Loading clinical trials...

Efficacy and Safety of Single-port Surgical Robot System in Thoraic Surgery | Clinical Trials | Clareo Health

RECRUITINGNA

Efficacy and Safety of Single-port Surgical Robot System in Thoraic Surgery

Efficacy and Safety of Single-port Surgical Robot System in Thoraic Surgery: A Prospective, Single Center Study

NCT06286150•The First Affiliated Hospital of Guangzhou Medical University

Summary

Robotic surgical systems have become a promising surgical assistance system, with unique advantages such as 3D high-definition visual system, highly flexible wrist-jointed instruments, and automatic fitering of hand tremors. Robotic surgical systems is applied in various fields including urology, general surgery, cardiothoracic surgery, head and neck surgery, and gynecology. Currently, the Da Vinci surgical robot system is the most widely used robot system globally. However, the Da Vinci robot system for single-port laparoscopic surgery has not yet been launched in China. Therefore, the investigators conduct a prespective, single-center study to evaluate the efficacy and safety of single-port surgical robot system in thoracic surgery.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age between 18 and 75 years, regardless of gender.
•Patients who require endoscopic surgical treatment and have indications for lung segment/lobe resection; for pre-trial subjects, there is no restriction on the type of procedure, and inclusion is based on the investigator's judgment of having indications for thoracic surgery.
•Preoperative ASA classification of I-III.
•Voluntary participation in the clinical trial and willingness to provide informed.
•consent, either by the subject or their guardian.
•Willingness to cooperate and complete trial follow-up and related examinations.

Exclusion Criteria

•Patients with a history of thoracic surgery or previous history of other malignant tumors deemed unsuitable for inclusion by the investigator.
•Patients with severe comorbidities (cardiac, pulmonary, hepatic, cerebral, renal diseases) or physical weakness who cannot tolerate general anesthesia or surgery.
•Patients with severe bleeding tendencies or coagulation disorders.
•Patients in the active phase of infectious diseases or with other severe non-communicable infections.
•Patients positive for Human Immunodeficiency Virus (HIV) antibodies or syphilis seropositive patients.
•Patients with a suspected or confirmed alcohol, drug, or substance addiction.
•Patients with a history of epilepsy, mental illness, or cognitive impairment.
•Women who are pregnant, breastfeeding, or planning to become pregnant during the trial period.
•Participation in other interventional clinical trials within 3 months prior to signing the informed consent form.
•Other situations in which the investigator deems inappropriate for participation in this clinical trial.

Locations (1)

The First Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China

Key Dates

Start Date

September 15, 2023

Primary Completion Date

July 15, 2025

Completion Date

July 15, 2027

Last Updated

February 29, 2024

Enrollment

ESTIMATED participants

Conditions

Lung Cancer

Interventions

Surgical robot system

PROCEDURE

Contacts

Jianxing He, M.D.

CONTACT

+86-20-83337792 hejx@vip.163.com

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

NCT06305754

Non-small Cell Lung Cancer (NSCLC)

View study

RECRUITINGPHASE2

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

NCT05198830

Lung AdenocarcinomaLung Large Cell Carcinoma+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 29, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy and Safety of Single-port Surgical Robot System in Thoraic Surgery

Inclusion Criteria

Exclusion Criteria

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Magnetic Resonance Imaging of the Lung: Oncological Applications